These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19688780)

  • 1. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment in the cost-disutility plane.
    Eckermann S; Briggs A; Willan AR
    Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost estimates and uncertainty: the expected value technique.
    Hosp Cost Manag Account; 1992 May; 4(2):1-8. PubMed ID: 10117914
    [No Abstract]   [Full Text] [Related]  

  • 6. Regarding probabilistic analysis and computationally expensive models: necessary and required?
    Caro JJ; Getsios D; Möller J
    Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
    [No Abstract]   [Full Text] [Related]  

  • 7. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.
    Hoch JS; Rockx MA; Krahn AD
    BMC Health Serv Res; 2006 Jun; 6():68. PubMed ID: 16756680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
    Barton GR; Briggs AH; Fenwick EA
    Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adoption of cost-effectiveness acceptability curves in cost-utility analyses.
    Meckley LM; Greenberg D; Cohen JT; Neumann PJ
    Med Decis Making; 2010; 30(3):314-9. PubMed ID: 19773582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
    Elbasha EH
    Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stochastic league tables: an application to diabetes interventions in the Netherlands.
    Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
    Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
    O'Brien BJ; Briggs AH
    Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.
    Fenwick E; O'Brien BJ; Briggs A
    Health Econ; 2004 May; 13(5):405-15. PubMed ID: 15127421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
    Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
    Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
    Fenwick E; Marshall DA; Levy AR; Nichol G
    BMC Health Serv Res; 2006 Apr; 6():52. PubMed ID: 16623946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Representing uncertainty: the role of cost-effectiveness acceptability curves.
    Fenwick E; Claxton K; Sculpher M
    Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty.
    Yaesoubi R; Kunst N
    Med Decis Making; 2024 Oct; 44(7):770-786. PubMed ID: 39056310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.